Towa Pharmaceutical Yönetim

Yönetim kriter kontrolleri 1/4

Towa Pharmaceutical CEO'su Itsuro Yoshida, Jun1996 tarihinde atandı, in görev süresi 28.42 yıldır. şirketin hisselerinin 2.96% doğrudan sahiptir ve bu hisselerin değeri € 27.49M dir. Yönetim ekibinin ve yönetim kurulunun ortalama görev süresi sırasıyla 0.8 yıl ve 3.4 yıldır.

Anahtar bilgiler

Itsuro Yoshida

İcra Kurulu Başkanı

n/a

Toplam tazminat

CEO maaş yüzdesi	n/a
CEO görev süresi	28.4yrs
CEO sahipliği	3.0%
Yönetim ortalama görev süresi	less than a year
Yönetim Kurulu ortalama görev süresi	3.4yrs

Son yönetim güncellemeleri

Recent updates

CEO

Itsuro Yoshida (73 yo)

28.4yrs

Görev süresi

Mr. Itsuro Yoshida has been the President at Towa Pharmaceutical Co. Ltd. since June 1996. Mr. Yoshida joined Towa Pharmaceutical Co., Ltd.in May 1979 and served as its Manager of Accounting since May 198...

Liderlik Ekibi

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
Itsuro Yoshida	President & Representative Director	28.4yrs	Veri yok	2.96% € 27.5m
Shiro Hatagami	Executive Officer and GM of Accounting & Finance Division	less than a year	Veri yok	Veri yok
Norikazu Inoue	Executive Officer & GM of Administration Division	less than a year	Veri yok	0.0024% € 22.7k
Shigeki Fujita	Operating Officer & GM of Human Resource Development Center	less than a year	Veri yok	Veri yok
Yutaka Okuda	Senior OO & Division Manager of R&D Division and Unit Manager of Innovative Tech Research Unit	less than a year	Veri yok	Veri yok
Masao Tanaka	Director	no data	Veri yok	0.016% € 145.4k
Tetsuro Tabata	Senior Executive Officer & GM of Production Division	less than a year	Veri yok	Veri yok
Takeshi Sugiura	Executive Officer	no data	Veri yok	Veri yok
Yasuyuki Oishi	Executive Officer	no data	Veri yok	Veri yok

0.8yrs

Ortalama Görev Süresi

70yo

Ortalama Yaş

Deneyimli Yönetim: 6QC 'un yönetim ekibi deneyimli olarak kabul edilmiyor ( 0.8 yıl), bu da yeni bir ekibin varlığını gösteriyor.

Yönetim Kurulu Üyeleri

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
Itsuro Yoshida	President & Representative Director	40.9yrs	Veri yok	2.96% € 27.5m
Masao Tanaka	Director	7.4yrs	Veri yok	0.016% € 145.4k
Masaaki Takeyasu	Director	less than a year	Veri yok	0.0014% € 13.2k
Nobuki Ando	Independent Outside Director	less than a year	Veri yok	Veri yok
Norikazu Eiki	Independent Outside Director	9.4yrs	Veri yok	Veri yok
Osamu Uchikawa	Director	1.4yrs	Veri yok	0.0045% € 41.6k
Kaori Oishi	Independent Outside Director	4.4yrs	Veri yok	Veri yok
Kenryo Goto	Independent Outside Director	3.4yrs	Veri yok	Veri yok
Toshikazu Kokubun	Director	less than a year	Veri yok	0.0018% € 17.0k

3.4yrs

Ortalama Görev Süresi

66yo

Ortalama Yaş

Deneyimli Yönetim Kurulu: 6QC 'nin yönetim kurulu üyeleri deneyimli olarak kabul edilir (ortalama görev süresi 3.4 yıldır).

Towa Pharmaceutical Yönetim

Yönetim kriter kontrolleri 1/4

Anahtar bilgiler

Son yönetim güncellemeleri

Less than half of directors are independent

Towa Pharmaceutical Co., Ltd. Announces Board and Committee Resignations

Towa Pharmaceutical Co., Ltd., Annual General Meeting, Jun 25, 2024

Less than half of directors are independent

Towa Pharmaceutical Co., Ltd., Annual General Meeting, Jun 27, 2023

Less than half of directors are independent

Recent updates

Upcoming dividend of JP¥30.00 per share

Towa Pharmaceutical Co., Ltd. to Report Q2, 2025 Results on Nov 12, 2024

First quarter 2025 earnings released: EPS: JP¥112 (vs JP¥96.50 in 1Q 2024)

Final dividend of JP¥30.00 announced

New minor risk - Earnings quality

Less than half of directors are independent

Towa Pharmaceutical Co., Ltd. to Report Q1, 2025 Results on Aug 08, 2024

Towa Pharmaceutical Co., Ltd. Files New Drug Application (NDA) to the Ministry of Health, Labour and Welfare (MHLW) in Japan for the Rivastigmine Twice Weekly Transdermal Patch for Treating Mild to Moderate Dementia Associated with Alzheimer's Disease

Towa Pharmaceutical Co., Ltd. Files New Drug Application (NDA) to the Ministry of Health, Labour and Welfare (MHLW) in Japan for the Rivastigmine Twice Weekly Transdermal Patch for Treating Mild to Moderate Dementia Associated with Alzheimer's Disease

Towa Pharmaceutical Co., Ltd. Announces Board and Committee Resignations

Full year 2024 earnings released: EPS: JP¥329 (vs JP¥44.72 in FY 2023)

Towa Pharmaceutical Co., Ltd., Annual General Meeting, Jun 25, 2024

Upcoming dividend of JP¥30.00 per share

Towa Pharmaceutical Co., Ltd. to Report Fiscal Year 2024 Results on May 14, 2024

New minor risk - Share price stability

Third quarter 2024 earnings released: EPS: JP¥92.75 (vs JP¥14.38 loss in 3Q 2023)

Towa Pharmaceutical Co., Ltd. to Report Q3, 2024 Results on Feb 13, 2024

Second quarter 2024 earnings released: EPS: JP¥44.76 (vs JP¥26.35 in 2Q 2023)

Towa Pharmaceutical Co., Ltd. to Report Q2, 2024 Results on Nov 13, 2023

Upcoming dividend of JP¥30.00 per share at 2.1% yield

Investor sentiment improves as stock rises 18%

First quarter 2024 earnings released: EPS: JP¥96.50 (vs JP¥28.34 in 1Q 2023)

Less than half of directors are independent

Towa Pharmaceutical Co., Ltd. to Report Q1, 2024 Results on Aug 10, 2023

New major risk - Dividend sustainability

Towa Pharmaceutical Co., Ltd., Annual General Meeting, Jun 27, 2023

Full year 2023 earnings released: EPS: JP¥44.72 (vs JP¥323 in FY 2022)

Upcoming dividend of JP¥30.00 per share at 3.2% yield

Third quarter 2023 earnings released: JP¥14.38 loss per share (vs JP¥117 profit in 3Q 2022)

Towa Pharmaceutical Co., Ltd. to Report Q3, 2023 Results on Feb 13, 2023

Less than half of directors are independent

Upcoming dividend of JP¥30.00 per share

Towa Pharmaceutical Co., Ltd. to Report Q2, 2023 Results on Nov 14, 2022

First quarter 2023 earnings released: EPS: JP¥28.34 (vs JP¥108 in 1Q 2022)

Towa Pharmaceutical Co., Ltd. to Report Q1, 2023 Results on Aug 10, 2022

Full year 2022 earnings released: EPS: JP¥323 (vs JP¥284 in FY 2021)

Towa Pharmaceutical Co., Ltd., Annual General Meeting, Jun 24, 2022

Less than half of directors are independent

Towa Pharmaceutical Co., Ltd. to Report Fiscal Year 2022 Results on May 13, 2022

Upcoming dividend of JP¥33.00 per share

Third quarter 2022 earnings: EPS in line with expectations, revenues disappoint

Second quarter 2022 earnings released: EPS JP¥79.88 (vs JP¥59.25 in 2Q 2021)

Investor sentiment deteriorated over the past week

First quarter 2022 earnings released: EPS JP¥108 (vs JP¥67.77 in 1Q 2021)

Less than half of directors are independent

Full year 2021 earnings released: EPS JP¥284 (vs JP¥295 in FY 2020)

CEO

Görev süresi

Liderlik Ekibi

Ortalama Görev Süresi

Ortalama Yaş

Yönetim Kurulu Üyeleri

Ortalama Görev Süresi

Ortalama Yaş